Antipsychotic Trials in Schizophrenia

The CATIE Project

T Scott Stroup editor Jeffrey A Lieberman editor

Format:Hardback

Publisher:Cambridge University Press

Published:1st Apr '10

Currently unavailable, and unfortunately no date known when it will be back

Antipsychotic Trials in Schizophrenia cover

This book presents the results of the landmark CATIE study, a long and comprehensive study of schizophrenia.

CATIE was the largest, longest and most comprehensive study of schizophrenia to date. This book presents the definitive archival results of this landmark study, with chapters focused on specific outcomes, setting the findings in a wider context. Essential reading for psychiatrists, psychiatric researchers, mental health policy makers and pharmaceutical companies.Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.

'… important and timely …' Doody's
'This book is not just a reprint of all published CATIE papers - it takes us beyond the hype of the first publication by reminding us of the breadth and depth of the trial … This book will be of major interest to anyone involved in psychopharmacology. However, the richness of the use of social and cognitive end points means that there is a wealth of information for those who have no interest in antipsychotics but are interested in the lives and outcomes of people with schizophrenia.' The British Journal of Psychiatry

ISBN: 9780521895330

Dimensions: 240mm x 20mm x 161mm

Weight: 700g

330 pages